Rabies remains a significant global public health concern, particularly in Asia and Africa, affecting over 150 countries and territories. This viral, zoonotic, and often neglected disease claims tens of thousands of lives annually, with a disproportionate impact on children under 15, who account for 40% of fatalities. The primary mode of transmission to humans is through bites and scratches from infected dogs, which are responsible for 99% of human rabies cases. Fortunately, rabies is entirely preventable through widespread dog vaccination and effective bite prevention strategies. Once clinical symptoms manifest, rabies is invariably fatal. However, prompt post-exposure prophylaxis (PEP) can effectively halt the virus’s progression to the central nervous system, saving lives. PEP involves thorough wound washing, timely administration of a rabies vaccine, and, when necessary, rabies immunoglobulins. The World Health Organization (WHO) and its partners are committed to eradicating human deaths from dog-mediated rabies by 2030 through a comprehensive One Health approach.
Understanding Dog-Mediated Rabies
Rabies is a viral disease that targets the central nervous system and is transmissible between animals and humans. Dogs are the main culprits in transmitting the virus to humans, accounting for up to 99% of human rabies cases. Children aged 5 to 14 years are particularly vulnerable. While rabies can infect various mammals, including cats, livestock, and wildlife, dogs are the most significant vector for human infection. The virus spreads primarily through the saliva of infected animals, typically via bites, scratches, or contact with mucous membranes like the eyes, mouth, or open wounds. The economic impact of rabies is substantial, with annual global costs estimated at US$8.6 billion, encompassing lost lives, reduced livelihoods, medical expenses, and psychological trauma.
Globally, an estimated 59,000 deaths occur annually due to rabies, though documented figures often fall short of this estimate due to underreporting. Rabies is classified as a neglected tropical disease (NTD), disproportionately affecting marginalized communities who often lack access to or cannot afford effective human vaccines and immunoglobulins. The cost of PEP, including travel and lost income, can amount to US$108 on average, posing a significant financial burden for individuals living on as little as US$1–2 per day. Despite these challenges, over 29 million people worldwide receive the human rabies vaccine each year.
Rabies from Non-Canine Sources
In regions like the Americas, where dog-mediated rabies has been largely controlled, hematophagous bats have emerged as the primary source of human rabies infections. Bat-mediated rabies also poses an increasing threat in Australia and parts of western Europe. While deaths resulting from exposure to wild mammals like foxes and raccoons are rare, bites from rodents are not known to transmit rabies. Extremely rare transmission routes include inhaling virus-containing aerosols, consuming raw meat or milk from infected animals, or organ transplantation. Human-to-human transmission through bites or saliva is theoretically possible but has never been definitively confirmed.
Recognizing Rabies Symptoms
The incubation period for rabies typically spans 2–3 months but can range from one week to over a year, influenced by factors such as the virus entry site and viral load. Initial symptoms are often non-specific, including fever, pain, and unusual sensations like tingling, pricking, or burning at the wound site. As the virus progresses to the central nervous system, it causes inflammation of the brain and spinal cord, leading to severe neurological deficits. While clinical rabies can be managed, recovery without lasting neurological damage is exceedingly rare.
There are two distinct forms of rabies:
- Furious Rabies: Characterized by hyperactivity, extreme excitability, hallucinations, lack of coordination, hydrophobia (fear of water), and aerophobia (fear of drafts). This form often leads to death within days due to cardiorespiratory arrest.
- Paralytic Rabies: Accounts for approximately 20% of human cases and progresses more slowly than the furious form. Paralysis typically begins at the wound site and gradually spreads, leading to a coma and eventual death. This form is frequently misdiagnosed, contributing to under-reporting.
Diagnosing Rabies
Currently, there are no WHO-approved diagnostic tools for detecting rabies infection before the onset of clinical symptoms. Diagnosing rabies based on clinical signs alone can be challenging without a confirmed history of exposure to a rabid animal or the presence of specific symptoms like hydrophobia or aerophobia. Accurate risk assessment is paramount in determining the necessity of PEP. Once symptoms appear and the disease becomes untreatable, providing comprehensive and compassionate palliative care is recommended. Postmortem confirmation of rabies infection can be achieved through various laboratory techniques that detect viral antigens or nucleic acids in infected tissues. When possible, testing the biting animal is also crucial.
Effective Prevention Strategies
Canine Vaccination: The Cornerstone of Prevention
Mass vaccination programs targeting dogs, including puppies, represent the most cost-effective strategy for preventing rabies in humans by interrupting transmission at its source. It is important to note that culling free-roaming dogs has proven ineffective in controlling rabies.
Public Awareness and Education
Public education initiatives play a vital role in rabies prevention. These programs should target both children and adults, covering essential topics such as understanding dog behavior, bite prevention techniques, appropriate actions to take if bitten or scratched by a potentially rabid animal, and the importance of responsible pet ownership. These educational efforts are crucial complements to rabies vaccination programs.
Human Vaccination: PrEP and PEP
Effective human vaccines are available for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). PrEP is recommended for individuals in high-risk occupations, such as laboratory workers handling live rabies and related viruses, and for those whose activities may lead to direct contact with infected animals, including animal control staff and wildlife rangers. PrEP may also be indicated for recreational activities or travel in rabies-endemic areas, or for individuals residing in remote regions with limited access to rabies biologics. It is crucial to remember that PrEP does not eliminate the need for PEP; anyone exposed to a suspected rabid animal must still seek post-exposure care.
PEP serves as an emergency response to rabies exposure, preventing the virus from reaching the central nervous system. A robust PEP protocol involves:
- Extensive Wound Washing: Thoroughly cleaning the wound with soap and water for at least 15 minutes immediately after exposure.
- Rabies Vaccine Course: Administering a prescribed course of rabies vaccine.
- Rabies Immunoglobulin/Monoclonal Antibodies: Administering these when indicated, often into the wound site.
Exposure Risk and PEP Indications
The decision to administer a full PEP course depends on the severity of the exposure:
| Categories of Contact with Suspect Rabid Animal | Post-Exposure Prophylaxis Measures |
|---|---|
| Category I: Touching or feeding animals, animal licks on intact skin (no exposure) | Washing of exposed skin surfaces; no PEP required. |
| Category II: Nibbling of uncovered skin, minor scratches or abrasions without bleeding (exposure) | Wound washing and immediate vaccination. |
| Category III: Single or multiple transdermal bites or scratches, contamination of mucous membrane or broken skin with saliva from animal licks, exposures due to direct contact with bats (severe exposure) | Wound washing, immediate vaccination, and administration of rabies immunoglobulin/monoclonal antibodies. |
Exposures falling under Category II and III necessitate human rabies vaccination.
Ensuring Vaccine Quality and Administration
WHO mandates that all human rabies vaccines adhere to WHO standards to ensure their quality and efficacy. The use of substandard rabies vaccines has unfortunately led to public health failures in several countries.
WHO recommends transitioning from intramuscular (IM) to intradermal (ID) administration of human rabies vaccines. This shift significantly reduces the required vaccine volume and the number of doses, thereby cutting costs by 60–80% without compromising safety or efficacy. A reduced dosage regimen also enhances patient compliance with the recommended treatment plan.
WHO’s Commitment to Rabies Control
Rabies is prominently featured in WHO’s 2021–2030 Roadmap for the Global Control of Neglected Tropical Diseases (NTDs). This roadmap outlines progressive regional targets aimed at eradicating human deaths from dog-mediated rabies by 2030, a goal often referred to as “Zero by 30.” Key strategies include:
- Enhancing Access to Human Rabies Vaccines: Through collaborative efforts with partners like Gavi, the Vaccine Alliance, WHO is working to improve access to essential vaccines.
- Providing Technical Guidance: Supporting countries in developing and implementing national rabies elimination plans, with a strong focus on strengthening surveillance and reporting systems.
- Building Workforce Capacity: Encouraging countries to develop the capacity of their One Health workforce, utilizing rabies elimination programs as a platform for multisectoral collaboration.
- Promoting United Against Rabies (UAR): Advocating for increased action and investment in rabies control through the UAR multi-stakeholder forum, a collaboration involving WHO, the Food and Agriculture Organization (FAO), and the World Organisation for Animal Health (WOAH).